Takeda is the latest company to work with Sosei Heptares to develop a drug that regulates GPCR targets

 Takeda reported Monday that Takeda has formed a partnership with Sosoi Heptares that could be worth more than $1.2 billion to develop drugs that regulate targets that include small molecules and biologic G-protein joints (GPCR). The collaboration will focus first on Takeda's high-priority gastrointestinal goals, but will also include the potential to expand into other therapeutic areas.Hicks, head of drug discovery at Takeda Gastroenterology, said the treatment proposed through the collaboration provides an exciting way to detect inflammation of the intestines and movement disorders. Sosei Heptares points out that Takeda's chosen target represents a new treatment intervention for a range of diseases.under the terms of the agreement, Takeda will make an upfront and near-term payment of $26 million to Sosoi Heptares, which is eligible for future milestone payments that could exceed $1.2 billion, as well as tiered sales royalties. In return, Takeda will receive exclusive global rights to develop and commercialize therapeutics for each new target through a specific pharmacological approach in collaboration.last month, Roche's Genentech division signed an agreement with Sosei Heptares to develop small molecules and biologics to regulate GPCR targets for a range of diseases. Sosei will also work with Companies including Pfizer, Jitsubo Andreo pharmaceuticals to focus on a number of deals that target GPCR drugs. （cyy123.com）